The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

por Van Cutsem, Eric, Mayer, Robert J., Laurent, Stéphanie, Winkler, Robert, Grávalos, Cristina, Benavides, Manuel, Longo-Munoz, Federico, Portales, Fabienne, Ciardiello, Fortunato, Siena, Salvatore, Yamaguchi, Kensei, Muro, Kei, Denda, Tadamichi, Tsuji, Yasushi, Makris, Lukas, Loehrer, Patrick, Lenz, Heinz-Josef, Ohtsu, Atsushi
Publicado 2017

Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study

por García-Alfonso, Pilar, Muñoz, Andrés, Jiménez-Castro, Jerónimo, Jiménez-Fonseca, Paula, Pericay, Carles, Longo-Muñoz, Federico, Reyna-Fortes, Carmen, Argilés-Martínez, Guillem, González-Astorga, Beatriz, Gómez-Reina, María José, Ruiz-Casado, Ana, Rodríguez-Salas, Nuria, López-López, Rafael, Carmona-Bayonas, Alberto, Conde-Herrero, Verónica, Aranda, Enrique
Publicado 2021

Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors

por Auclin, Edouard, Vuagnat, Perrine, Smolenschi, Cristina, Taieb, Julien, Adeva, Jorge, Nebot-Bral, Laetitia, Garcia de Herreros, Marta, Vidal Tocino, Rosario, Longo-Muñoz, Federico, El Dakdouki, Yola, Martín-Romano, Patricia, Gaba, Lydia, Saurí, Tamara, Oliveres, Helena, Castañón, Eduardo, Garcia-Carbonero, Rocio, Besse, Benjamin, Massard, Christophe, Mezquita, Laura, Hollebecque, Antoine
Publicado 2021